Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update [Yahoo! Finance]
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at
Wall Street
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $67.00. They now have an "overweight" rating on the stock.
Cogent Biosciences: Time For A Pause [Seeking Alpha]